Palvella Therapeutics (PVLA) Projected to Release Quarterly Earnings on Tuesday

Palvella Therapeutics (NASDAQ:PVLA) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Palvella Therapeutics to announce earnings of ($1.17) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, analysts expect Palvella Therapeutics to post $-5 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA traded up $2.09 during trading on Monday, reaching $141.13. The stock had a trading volume of 30,796 shares, compared to its average volume of 277,897. The stock has a market cap of $2.02 billion, a PE ratio of -33.59 and a beta of -0.17. The firm’s 50 day moving average price is $130.19 and its two-hundred day moving average price is $118.41. Palvella Therapeutics has a one year low of $36.00 and a one year high of $161.38.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. HC Wainwright reissued a “buy” rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Stephens reissued an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $199.53.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several large investors have recently made changes to their positions in the business. Group One Trading LLC raised its stake in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at $36,000. JPMorgan Chase & Co. boosted its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $85,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Palvella Therapeutics during the second quarter worth $104,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.